Marc Lajoie, Outpace Bio CEO
May 26, 2023 10:37 AM EDT
R&D
Cell/Gene Tx

Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

Tyler Patchen

News Reporter

Out­pace Bio, a Seat­tle-based biotech that aims to cre­ate cell ther­a­pies, has ce­ment­ed its pres­ence in the Emer­ald City with a new fa­cil­i­ty and a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times